Диссертация (1140221), страница 27
Текст из файла (страница 27)
2016 Sep; 94(3):275-9161. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venousthromboembolism in young women: a case-control study // Int J Epidemiol1992;21:48-52.162. Tormene D, Grandone E, De Stefano V. - Obstetric complications andpregnancy-related venous thromboembolism: the effect of low-molecular-weightheparin on their prevention in carriers of factor V Leiden or prothrombin G20210Amutation // Thromb Haemost. 2012;107(3):477–484163.
Van Boven H.H., Reistma P.H., Rosendaal F.R. et al. Factor V Leiden (FVR506Q) in families with inherited antithrombin deficiency. // Thromb Haemost 1996;75: 417.164. Van der Linden, den Heijer M., Afman L.A., Gellekink H. The methioninesynthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida// J Mol Med (Berl). 2006 Dec;84(12):1047-54.165.
Van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.The effect of 2 combined oral contraceptives containing either drospirenone orcyproterone acetate on acne and seborrhea // Cutis 2002;69:2-15.166. Vandenbroucke J.P., Helmerhorst F.M., Bloemenkamp KW, Rosendaal FR.Third-generation oral contraceptive and deep venous thrombosis: fromepidemiologic controversy to new insight in coagulation // Am J Obstet Gynecol1997;177:887-91.167.
Vandenbroucke J.P., Koster T., Briët E., Reitsma P.H., Bertina R.M., RosendaalF.R. Increased risk of venous thrombosis in oral-contraceptive users who arecarriers of factor V Leiden mutation // Lancet, 1994;344:1453-7.168. Vandenbroucke J.P., van der Meer F.J, Helmerhorst F.M., Rosendaal F.R. FactorV Leiden: should we screen oral contraceptive users and pregnant women? // BMJ.1996 Nov 2;313(7065):1127-30.168169.Vernon E., Hiedemann B., Bowie B. - Economic Evaluations of ThrombophiliaScreening Prior to Prescribing Combined Oral Contraceptives: A Systematic andCritical Review.
// Appl Health Econ Health Policy 2017 (3), 1-13 p.170. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venousthromboembolism: findings in a large prospective study // BMJ 1986;292:526.171.Visser J, Ulander VM, Helmerhorst FM. Thromboprophylaxis for recurrentmiscarriage in women with or without thrombophilia. HABENOX: a randomisedmulticentre trial // Thromb Haemost. 2011;105(2):295–301.172. Vlachadis N., Tsamadias V., Vrachnis N. Associations of combinedpolymorphisms of the platelet membrane glycoproteins Ia and IIIa and the plateletendothelial cell adhesion molecule-1 and P-Selectin genes with IVF implantationfailures // J Obstet Gynaecol. 2017 Apr; 37(3):363-369.173. Vlieg H.A., Helmerhorst F M, Vandenbroucke J P, Doggen C J M, Rosendaal FR - The venous thrombotic risk of oral contraceptives, effects of oestrogen dose andprogestogen type: results of the MEGA case-control study // BMJ 2009; 339:b2921,doi:10.1136/bmj.b2921174.
Vlieg HA, Frolich M, Christella M, Thomassen MCLGD, Doggen CJM,Rosendaal FR, et al. Association between sex hormone-binding globulin levels andactivated protein C resistance in explaining the risk of thrombosis in users of oralcontraceptives containing different progestogens // Hum Reprod 2005;20:563-8175. WHO. Effect of different progestagens in low oestrogen oral contraceptives onvenous thromboembolic disease.
World Health Organization Collaborative Studyof Cardiovascular Disease and Steroid Hormone Contraception // Lancet1995;346:1582176. WHO. Selected practice recommendations for contraceptive use. Fifth edition.Geneva, 2015.177. WHO. Venous thromboembolic disease and combined oral contraceptives:Results of international multicentre case-control study. World Health OrganizationCollaborative Study of Cardiovascular Disease and Steroid Hormone Contraception// Lancet 1995;346:1575–82.169178.
Wiegratz I, Lee JH, Kutschera E. et al. Effect of four oral contraceptives onhemostatic parameters // Contraception. 2004; 70:2:97-106.179. Wolf C.E., Haubelt H., Pauer H.U., Hinney B., Krome-Cesar C, Legler T.J. etal. Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A andpolymorphisms of plasminogen activator and plasminogen activator inhibitor //Pathophysiol Haemost Thromb. 2003;33(3):134–137. doi: 10.1159/000077821180. Wright K.P., Johnson J.V.
Evaluation of extended and continuous use oralcontraceptives // Ther Clin Risk Manag. 2008 Oct; 4(5): 905–911..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
